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Abstract
Glutathione (GSH) and GSH-associated metabolism provide the major line of defense for the
protection of cells from oxidative and other forms of toxic stress. Of the three amino acids that
comprise GSH, cysteine is limiting for GSH synthesis. Since extracellularly cysteine is readily
oxidized to form cystine, cystine transport mechanisms are essential to provide cells with cysteine.
Cystine uptake is mediated by system xc−, a Na+-independent cystine/glutamate antiporter. Inhibition
of system xc− by millimolar concentrations of glutamate, a pathway termed oxidative glutamate
toxicity, results in GSH depletion and nerve cell death. Recently, we described a series of compounds
derived from the conjugation of epicatechin with cysteine and cysteine derivatives that protected
nerve cells in culture from oxidative glutamate toxicity by maintaining GSH levels. In this paper, we
characterize an additional epicatechin conjugate, cysteamine-epicatechin, that is 5-10 fold more
potent than the earlier conjugates. In addition, we show that these epicatechin conjugates maintain
GSH levels by enhancing the uptake of cystine into cells through induction of a disulfide exchange
reaction, thereby uncoupling the uptake from system xc−. Thus, these novel epicatechin conjugates
have the potential to enhance GSH synthesis under a wide variety of forms of toxic stress.
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Introductory Statement
Glutathione (GSH) and GSH-associated metabolism provide the major line of defense for the
protection of cells from oxidative and other forms of toxic stress. GSH can scavenge free
radicals, reduce peroxides and be conjugated with electrophilic compounds, thereby
eliminating both reactive oxygen species (ROS) and their toxic by-products (Dickinson &
Forman 2002, Hayes & McLellan 1999). In addition, the GSSG/GSH redox pair forms the
major redox couple in cells and as such plays a critical role in regulating redox-dependent
cellular functions (Schafer & Buettner 2001).
GSH is a tripeptide consisting of the amino acids cysteine, glutamate and glycine. Intracellular
GSH levels are regulated by a complex series of mechanisms that include substrate availability
and transport, rates of synthesis and regeneration, GSH utilization and GSH efflux to
extracellular compartments (Meister & Anderson 1983). Because glutamate and glycine occur
at relatively high intracellular concentrations, cysteine is limiting for GSH synthesis in many
types of cells, including nerve cells (Wu et al. 2004). In the extracellular environment, cysteine
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is readily oxidized to form cystine, so for most cell types, cystine transport mechanisms are
essential to provide them with the cysteine needed for GSH synthesis (Wu et al. 2004).
Cystine uptake in many types of cells is mediated by system xc−, a Na+-independent cystine/
glutamate antiporter (Sato et al. 1999). System xc− is a member of the disulfide-linked
heteromeric amino acid transporter family and consists of a light chain (xCT) that confers
substrate specificity and a heavy chain (4F2hc) that is shared among a number of different
amino acid transporters (Wagner et al. 2001). It transports cystine into cells in a 1:1 exchange
with glutamate and is thus inhibited by high concentrations of extracellular glutamate (Murphy
et al. 1989). The importance of system xc− for the maintenance of GSH levels in cells is
demonstrated by the loss of GSH and subsequent cell death seen in nerve and other types of
cells following exposure to millimolar concentrations of extracellular glutamate, a pathway
termed oxidative glutamate toxicity or oxytosis (Tan et al. 2001). Furthermore, mice that lack
system xc− function, either via truncation (Shih et al. 2006) or deletion show brain atrophy and
redox imbalance (Sato et al. 2005), respectively.
GSH loss has been directly correlated with cell death following exposure of neural cells to a
wide range of insults (Maher 2005). In addition, GSH loss is associated with the cell death
seen in a variety of neurological disorders including Parkinson's disease, Alzheimer's disease,
and stroke (Bains & Shaw 1997, Maher 2006). Thus, treatments that can maintain GSH levels
in the presence of a GSH loss-inducing stress have a significant potential for the treatment of
neurological diseases.
Recently, we described a series of compounds derived from the conjugation of the flavonoid
epicatechin with cysteine and cysteine-related molecules that were significantly more effective
than the underivatized flavonoid at protecting nerve cells in culture from oxidative glutamate
toxicity (Torres et al. 2005). These compounds, which were obtained by acid depolymerization
of proanthocyanidins in the presence of the thiol (Torres et al. 2002), protect nerve cells by
maintaining GSH levels rather than scavenging free radicals through their phenolic moieties
(Torres et al. 2005). However, they all had relatively low potencies with EC50 values ranging
from 36-60 μM. In the work described below, we characterized an additional epicatechin
conjugate, cysteamine-epicatechin (Cya-EC), that is 5-10 fold more potent than any of the
earlier conjugates. In addition, we show that this novel epicatechin conjugate, as well as the
previously described epicatechin conjugates, maintain GSH levels by enhancing the uptake of
cystine/cysteine into cells by a mechanism that uncouples the uptake from system xc−. Thus,




Quisqualate was from Tocris. Homocysteic acid, cystine, cysteine, cysteamine, glutamate, 2-
aminobicyclo(2,2,1)heptane-2-carboxylic acid (BCH), methylaminoisobutyric acid (MAIBA),
L-β-threo-benzyl-aspartate (TBOA), arginine, L-serine and D-serine as well as all other
chemicals were from Sigma.
Preparation of the thioconjugates
Conjugates of epicatechin, epigallocatechin, epicatechin gallate and epigallocatechin gallate
with cysteamine, cysteine or cysteine derivatives were obtained by cleavage of polymeric
flavanols (proanthocyanidins) essentially as described (Torres & Bobet 2001, Lozano et al.
2006). The sources of epicatechins and epigallocatechins were grape pomace and witch hazel
stems, respectively. Briefly, the plant material was treated with the corresponding thiol in
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0.25% aqueous HCl at 90°C for 2h. The resulting conjugates were purified by cation-exchange
and reversed-phase liquid chromatography and characterized by electrospray mass
spectrometry (ESI-MS), high resolution mass spectrometry (HR-MS) and nuclear magnetic
resonance (NMR). ES-MS spectra were recorded on an Agilent 1100/API 3000 (Waldbronn,
Germany) system and HR-MS spectra were recorded on a LC/MSD-TOF (Agilent
Technologies, Santa Clara, CA) system. 1H-NMR spectra were observed with an Inova-500
MHz (Varian, Palo Alto, CA) apparatus for (CD3)OD and D2O solutions. The analytical data
for Cya-EC, Cya-ECG, Cys-EC, ECys-EC and AMCys-EC were measured and compared with
those already published (Torres & Bobet 2001, Lozano et al. 2006). The analytical data for
Cya-EGC and Cya-EGCG are reported here for the first time.
4ß-(2-aminoethylthio) epigallocatechin (Cya-EGC)—ES-MS positive ions, m/z 382.1
[M + 1]+; LC/MSD-TOF positive ions, m/z 382,09595 calculated for C17H20NO7S [M + H]+
382.09605; 1H-NMR (CD3)OD, 500 MHz): δ 3.06 (1H, dt J=15, 7 Hz, S-CH2-CH2-NH3+);
3.29 (1H, dt J=15, 5.5 Hz, S-CH2-CH2-NH3+); 3.47-3.58 (2H, m, S-CH2-CH2-NH3+); 4.04
(1H, d J=2.5 Hz, 4-H 3, 4-trans configuration); 4.20 (1H, d J=1.5 Hz, 3-H); 5.28 (1H, s, 2-H);
6.09 (1H, d J=2.0 Hz, 8-H); 6.16 (1H, d J=2.0 Hz, 6-H); 6.72 (2H, m, 2′-H, 6′-H).
4ß-(2-aminoethylthio) epigallocatechin 3-O-gallate(Cya-EGCG)—ES-MS positive
ions, m/z 534.1 [M + 1]+; LC/MSD-TOF positive ions, m/z 534.10651 calculated for
C24H24NO11S [M + H]+ 534.10701; 1H-NMR (D2O, 500 MHz): δ 2.98 (1H, dt J=15, 7.5 Hz,
S-CH2-CH2-NH3+); 3.28 (1H, dt J=15, 5.5 Hz, S-CH2-CH2-NH3+); 3.38-3.41 (2H, m, S-
CH2-CH2-NH3+); 4.05 (1H, d J=2.0 Hz, 4-H 3, 4-trans configuration); 5.10 (1H, bs, 3-H); 5.32
(1H, s, 2-H); 5.94 (1H, d J=2.0 Hz, 8-H); 5.96 (1H, d J=2.5 Hz, 6-H); 6.57 (2H, s, 2′-H, 6′-H);
6.84 (2H, s, galloyl-H).
Cell Culture and Viability Assays
HT22 cells were grown on tissue culture dishes in DMEM-high glucose supplemented with
10% FCS as described (Davis & Maher 1994). Primary rat cortical neurons were prepared and
grown as described (Maher 2001). Cell viability was determined by a modified version of the
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assay based on the
standard procedure (Hansen et al. 1989). The cells were plated into 96 well dishes at 5 × 103
cells/dish in complete medium and 18 hr later the medium was replaced with DMEM-high
glucose supplemented with 7.5% dialyzed FCS (DFCS) and the experimental agents were
added. In some experiments, cystine-free DMEM-high glucose supplemented with 7.5% DFCS
was used in order to deplete cystine from cells. 24 hr after the addition of the experimental
agents, the cell culture medium in each dish was aspirated and replaced with 100 μl DMEM-
high glucose with 7.5% DFCS containing 2.5 μg/ml MTT. After 4 hours of incubation at 37°
C, the cells were solubilized by the addition of 100 μl of a solution containing 50%
dimethylformamide and 20% SDS (pH 4.7). The absorbance at 570 nm was measured on the
following day with a microplate reader. Results obtained from the MTT assay correlated
directly with the extent of cell death as confirmed visually. Controls employing wells without
cells and cells without the experimental agents were used to determine the effects of agents
upon the assay chemistry or cell viability, respectively.
Total Intracellular GSH/GSSG
Cells were washed twice with ice-cold PBS, collected by scraping, and lysed with 3%
sulfosalicylic acid. Lysates were incubated on ice for 10 minutes and supernatants were
collected after centrifugation in an Eppendorf microfuge. Upon neutralization of the
supernatant with triethanolamine, the concentration of total glutathione (reduced and oxidized)
was determined by the method of Tietze (Tietze 1969) with modifications (Ishige et al.
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2001). The protein content of each sample was determined using the BCA Protein Assay kit
from Pierce (Rockford, IL) with BSA as a standard.
35S-Cystine Uptake
Cells were plated into 24 well dishes at 3 × 105 cells/well. 24 hr later the cells were rinsed 3
times with sodium-free (sodium replaced with choline chloride) or sodium-containing Hank's
Balanced Salt Solution (HBSS) and incubated with 25 μM 35S-cystine (Amersham) for 10-60
min in the same buffer as used for washing. The uptake was terminated by placing the dish on
ice and washing 3 times with ice-cold HBSS. The cells were solubilized by overnight
incubation in 500 μl 0.2 M NaOH. The radioactivity in a 150 μl aliquot was determined by
scintillation counting and normalized to protein determined using the Bradford Assay (Pierce).
Thiol exchange
Stock solutions of Cya-EC and L-Cystine (1 mg/ml) were used. L-Cystine (60 μl) was added to
Cya-EC (120 μl) and taken up to a final volume of 5 ml with Hanks balanced solution. The
final concentration of each compound was 50 μM. The solution was incubated at 37°C for 50
min. Samples were taken and kept frozen until the HPLC analysis.
Statistical Analysis
All statistical analyses were performed using InStat 3. The results were analyzed for statistically
significant differences at the p < 0.05 level using the analysis of variance (ANOVA) test and
Tukey's post test for individual group means comparisons. A minimum of three independent
experiments were used for statistical analyses.
Results
Similar to the previously described epicatechin conjugates (Torres et al. 2005) (Table 1),
cysteamine-epicatechin (Cya-EC) dose dependently protected the HT22 nerve cell line (Fig.
1A) from oxidative glutamate toxicity with an EC50 of ∼ 6 μM. Cya-EC also protected primary
neurons from glutamate (Fig. 1B). In addition, Cya-EC protected nerve cells from homocysteic
acid and quisqualate (Fig. 1C), two additional compounds that kill nerve cells by blocking
cystine uptake through system xc−. The cysteine and cysteine derivative epicatechin conjugates
were shown previously to protect cells via the maintenance of GSH levels (Torres et al.
2005). Similarly, as shown in Figure 2A, Cya-EC dose-dependently maintains GSH levels in
the presence of glutamate. Even after 8 hr of glutamate treatment when the levels of GSH have
fallen below the critical 20% level, HT22 cells treated with 10 μM Cya-EC maintained at least
50% of the control level of GSH (Fig. 2B). The effects of Cya-EC on both GSH levels and cell
survival in glutamate-treated cells is blocked by treatment with BSO, an inhibitor of GSH
synthesis (Griffith & Meister 1979) (Fig. 2C), demonstrating that Cya-EC acts at or before
GSH synthesis to increase GSH levels.
To understand how Cya-EC maintains GSH levels, we decided to examine its effects on each
of the steps in GSH metabolism, beginning with cystine uptake. Surprisingly, we found that
Cya-EC enhanced cystine uptake in a time- (Fig. 3A) and dose-dependent (Fig. 3B) manner.
There was an excellent correlation between increases in cystine uptake and increases in GSH
levels (Fig. 3C). Furthermore, in contrast to the results with glutamate toxicity, Cya-EC failed
to protect cells from cystine depletion (Fig. 3E). In the uptake experiments, Cya-EC was mixed
with 35S-cystine and then added directly to the cells for the 60 min uptake time point or after
incubation at 37°C for 10-50 min so that while the time for the treatment of the cells with the
mixture ranged from 10-60 min, the total incubation time for the mixture was always 60 min.
However, unexpectedly, when we began studies to tease out the mechanisms underlying the
effect of Cya-EC on cystine uptake and used only a 10 min total incubation time, we saw no
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effect (data not shown). In contrast, if we pre-incubated Cya-EC with 35S-cystine at 37°C
before adding the mixture to the cells for 10 min, then the enhancement of cystine uptake was
restored. Indeed, further studies showed a time dependent increase in 35S-cystine uptake
following pre-incubation with Cya-EC that reached a plateau after ∼50 min at 37°C (Fig. 3D).
These results suggested that there was a direct interaction between Cya-EC and cystine that
was not instantaneous and perhaps generated a product that was transported into cells by a
pathway distinct from system xc.
To examine the fate of Cya-EC upon incubation with cystine we mixed the compounds together
in HBSS and analyzed the mixture by reversed-phase high performance liquid chromatography
(RP-HPLC) at different times over a total period of 60 min. We observed a decrease in the
peak corresponding to Cya-EC and the appearance of a new, small peak corresponding to the
cysteine conjugate, Cys-EC (Fig 4). The same behavior was observed with the dimer of O-
ethyl-cysteine (data not shown). These results indicate that the cysteamine moiety of Cya-EC
can be replaced by other sulfur containing compounds which are present in the form of
disulfides.
To provide evidence for the idea that sulfur-containing compounds distinct from cystine can
be transported into cells upon treatment with Cya-EC, we first looked at the ability of glutamate
and quisqualate to inhibit cystine uptake. In control cells, 5 mM glutamate or 250 μM
quisqualate, a more specific inhibitor of system xc−, inhibited 35S-cystine uptake by ∼80%
(Fig. 5). In contrast, in cells treated with Cya-EC, both glutamate and quisqualate only
reduced 35S-cystine uptake by ∼30% (Fig. 5).
If the interaction of Cya-EC with cystine results in the generation of cysteine and eventually,
a mixed disulfide, cysteine could be taken up by cells through a variety of ubiquitously
expressed Na+–independent and –dependent transport systems distinct from system xc−
(Wagner et al. 2001, Hyde et al. 2003) while mixed disulfides could be taken up by the Na+-
independent system L (Ishii et al. 1981). Indeed, high concentrations of cysteamine have been
shown to increase 35S-cystine uptake into cells by this mechanism (Issels et al. 1988). To test
this idea, we first looked at the ability of cysteine to block the Cya-EC-dependent increase
in 35S-cystine uptake into cells. In these experiments, cysteine was added to the mixture of
Cya-EC and 35S-cystine after the 50 min incubation period and immediately before the addition
of the mixture to cells to preclude any effects on the interaction between Cya-EC and 35S-
cystine. As shown in Figure 5, 5 mM cysteine inhibited by 75% the Cya-EC dependent increase
in 35S-cystine uptake but had no effect on 35S-cystine uptake in control cells. In contrast, 5
mM cystine inhibited by ∼85% 35S-cystine uptake in control cells but had a much lesser effect
on 35S-cystine uptake in Cya-EC-treated cells (Fig. 5).
To determine which uptake systems for cysteine were responsible for the enhanced Cya-EC-
mediated uptake of 35S-cystine, we tested inhibitors of each of the different uptake systems
that have been shown to transport cysteine and/or the mixed disulfide for their effects on Cya-
EC-stimulated 35S-cystine uptake. Both system asc and system L can transport cysteine by
Na+-independent mechanisms (Wagner et al. 2001) and system L can also transport mixed
disulfides (Ishii et al. 1981). However, only an inhibitor of system L (BCH) but not an inhibitor
of system asc (D-serine) blocked the enhancement of Na+-independent 35S-cystine uptake by
Cya-EC (Fig. 6). System A, system ASC, EAATs and system Bo,+ can transport cysteine by
Na+-dependent mechanisms (Hyde et al. 2003). However, while an inhibitor of system ASC
(L-serine) blocked the enhancement of Na+-dependent 35S-cystine uptake by Cya-EC,
inhibitors of system A (methylaminoisobutyric acid (MAIBA)), EAATs (TBOA) and system
Bo,+ (arginine) had little or no effect. Although D-serine has been reported to inhibit system
ASC, this inhibition is specific for ASCT2 (Shafqat et al. 1993, Utsunomiya-Tate et al.
1996) while ASCT1 is the ASC transporter expressed in neurons (Yamamoto et al. 2004).
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To further validate these findings, we looked at the effects of the different inhibitors of cysteine
transport on both Cya-EC-mediated increases in GSH and cell survival in the presence of
glutamate. As shown in Figure 6, only the system ASC inhibitor L-serine significantly decreased
Cya-EC-mediated increases in GSH levels. L-serine also significantly decreased the effect of
Cya-EC on cell survival in the presence of toxic concentrations of glutamate while inhibitors
of the other transport systems, D-serine, MAIBA, TBOA and arginine, had little or no effect.
BCH by itself increased GSH levels and cell survival in the presence of glutamate and so its
effect on Cya-EC-mediated increases in GSH levels and protection from glutamate toxicity
could not be evaluated.
If Cya-EC increases 35S-cystine uptake by releasing cysteine from cystine through a
mechanism involving the cleavage of cystine with the eventual formation of a mixed disulfide
by the departing cysteamine moiety, then we would expect to see similar effects on 35S-cystine
uptake and cell survival with equivalent concentrations of cysteamine (Cya). As shown in
Figure 7A, this is indeed the case. 10 μM Cya enhances 35S-cystine uptake and this
enhancement is inhibited by both L-serine and BCH but not by MAIBA, TBOA, arginine or D-
serine (Fig. 7B). Cya also protects cells from oxidative glutamate toxicity and this protection
is inhibited by L-serine but not by MAIBA, TBOA, arginine or D-serine (Fig. 7B).
Several other EC conjugates have been shown to increase GSH levels and cell survival in the
HT22 cells (Torres et al. 2005). In addition, we made additional Cya conjugates including Cya-
epicatechin gallate (Cya-ECG), Cya-epigallocatechin (Cya-EGC) and Cya-epigallocatechin
gallate (Cya-EGCG) (Table 1), to determine if modification of epicatechin affected the ability
of the Cya conjugate to enhance GSH levels and protect cells from oxidative stress. While Cya-
ECG was reasonably effective at enhancing GSH levels (Fig. 8B) and protecting HT22 cells
from oxidative glutamate toxicity (Fig. 8B), the other modifications led to significant
reductions in potency and efficacy. Because the less effective cysteamine derivatives included
moieties (ECG, EGC, EGCG) more active than EC at scavenging free radicals, these results
confirmed our previous observation that scavenging of mitochondrial ROS does not play a
significant role in the protection against oxidative glutamate toxicity by these particular kinds
of compounds (Torres et al. 2005). We also looked at the ability of the cysteamine conjugates,
as well as the previously described EC conjugates (Cys-EC, AMCys-EC and ECys-EC) (Table
1), to enhance cystine uptake. Using a fixed concentration of 10 μM, we found that Cya-EC
was the most effective of all of the EC conjugates at increasing 35S-cystine uptake although
several of the other conjugates were also quite good including Cya-ECG (Fig. 8A). In contrast,
both Cya-EGC and Cya-EGCG were almost completely ineffective. The effects of the
conjugates on 35S-cystine uptake showed a good correlation with their effects on GSH levels
strongly suggesting that they increase GSH levels by a mechanism very similar to that of Cya-
EC.
Discussion
In these studies we describe a novel epicatechin derivative, Cya-EC, that enhances GSH levels
and cell survival by increasing cystine uptake into cells. It does so not by increasing the activity
of system xc−, but rather by reacting with cystine and releasing cysteine which can react with
the leaving cysteamine moiety to form the mixed disulfide Cya-Cys (Fig. 9), thereby allowing
these sulfur-containing compounds to enter cells via multiple transport systems. We have
preliminary data suggesting that the same reactions occur under physiological conditions. Cya-
EC is partially converted into Cys-EC when absorbed and metabolized in the small intestine,
probably through reaction with endogenous cystine (unpublished results).
Although a similar pathway was described for the enhancement of cystine uptake by
cysteamine in CHO cells (Issels et al. 1988) and N-acetyl cysteine (Phelps et al. 1992) in
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pulmonary artery endothelial cells, relatively high concentrations of cysteamine (0.4 mM) or
NAC (1 mM) were required for an effect to be seen in these studies. In contrast, we find that
Cya-EC is effective below 10 μM. However, in our system we also see a strong effect of
cysteamine at this concentration. Nevertheless, we believe that Cya-EC provides a better option
for enhancing cystine uptake into cells than cysteamine for several reasons. First, the presence
of the polyphenol group in Cya-EC is likely to modify the ability of the compound to cross the
blood-brain barrier or the blood-retina barrier, thereby allowing it access to two tissues, the
brain and the eye, where the ability to maintain GSH levels is of utmost importance. Indeed,
a glucuronidated and methylated metabolite of epicatechin has been detected in the brains of
rats and mice after oral ingestion of the intact polyphenol (El-Mohsen et al. 2002, van Praag
et al. 2007). This metabolite may be involved in the retention of spatial memory in mice fed
with EC (van Praag et al. 2007). While there could be some problems with Cya-EC crossing
membranes due to its charge, we also saw significant effects on 35S-cystine uptake with
uncharged cysteine derivatives such as AMCys-EC. Second, solutions of cysteamine tend to
oxidize. Cystamine, the oxidized form of cysteamine, is much less effective at promoting
cystine uptake (Wood et al. 2007). In contrast, cysteamine in the form of the epicatechin
conjugate cannot oxidize because it does not have a free thiol group. Furthermore, Cya-EC is
a potent inhibitor of bacterial lipopolysaccharide (LPS)-induced cytokine production (Mitjans
et al. 2004), a model for anti-inflammatory activity, with > 80% inhibition seen at 70 μM
whereas a similar level of anti-inflammatory activity was only seen in the presence of
millimolar concentrations of cysteamine (Ozaki et al. 2007).
The ability to enhance cystine uptake by converting it to cysteine and thereby shifting its uptake
to alternative transport systems could have a number of potential benefits. First, as indicated
in the Introductory Statement, system xc− is an antiporter, expelling one molecule of glutamate
for every molecule of cystine taken up into cells. There are a number of conditions, especially
in the brain, where increases in extracellular glutamate are not desirable because of its
interaction with ionotropic glutamate receptors. Therefore, a mechanism for increasing
cysteine, the rate limiting precursor for GSH synthesis, without increasing extracellular
glutamate, could be highly beneficial (e.g. Piani & Fontana 1994, Fogal et al. 2007). Second,
when brain glutamate is high, cystine uptake through system xc− is inhibited. The EC
derivatives allow cells to bypass this system. Furthermore, since cysteine uptake can occur
through a number of different transporters, it is less likely to be impacted by a specific insult.
Third, system xc− works in conjunction with glutamate transporters (Lewerenz et al. 2006).
Glutamate transporters have been shown to be quite sensitive to oxidative stress (Trotti et al.
1998). Thus, under conditions where it may be critical to increase GSH levels, system xc− may
not function efficiently. Cya-EC could provide an alternative for maintaining the cysteine
needed for GSH synthesis. Fourth, Cya-EC might be particularly useful under conditions of
lactacidosis which occurs during ischemia, head trauma, hyperglycemia and seizures (Lipton
1999). System xc− is impaired under these conditions (Bannai & Kitamura 1981, Koyama et
al. 2000), potentially leading to a deficiency in cystine uptake across the blood-brain barrier
where xCT expression is highest (Burdo et al. 2006). Cya-EC could ameliorate this impairment
and would not have to cross the blood-brain barrier to do so.
Cysteamine is neuroprotective in a variety of in vitro and in vivo models of neurodegenerative
diseases (for review see Wood et al. 2007). Although a number of mechanisms underlying this
neuroprotection have been proposed, it is likely that an important aspect is the ability of
cysteamine to increase intracellular thiol pools. This, in turn, will enhance the synthesis of
GSH and may also have additional protective effects (Wood et al. 2007).
The ability of cysteamine to react with cystine to produce cysteine and a mixed disulfide is
well known (Meier & Issels 1995). Other thiols share this property (Meier & Issels 1995), but
all of these compounds contain a free thiol group. Indeed, oxidation of the thiol or addition of
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a phosphate group abolished the ability of the compounds to promote cystine uptake (Meier &
Issels 1995). It is therefore somewhat surprising that the Cya-EC conjugate is able to promote
cystine uptake. However, the studies with the different cysteamine-epicatechin conjugates
suggest that epicatechin allows the cysteamine to readily react with disulfides but other
epicatechin-related compounds do not appear to be as effective at transferring their attached
sulfur-containing moiety.
Using inhibitors of a variety of ubiquitously expressed Na+–independent and –dependent
transport systems that are known to transport cysteine into cells, we found that only inhibitors
of the Na+–independent system L and the Na+-dependent system ASC altered the increase in
cyst(e)ine uptake promoted by treatment of the HT22 cells with Cya-EC. This is somewhat
surprising in that other studies that looked at the mechanisms underlying cysteine uptake in
nerve cells showed that glutamate transporters (EAATs) provided the major route for transport
(Shanker et al. 2001, Chen & Swanson 2003). While EAATs are expressed by the HT22 cells
(Lewerenz et al. 2006) both glutamate and the EAAT inhibitor, TBOA, had little or no effect
on cyst(e)ine transport. However, since Cya-EC is also able to promote the survival of primary
neurons in response to glutamate treatment it is unlikely that the promotion of cysteine transport
by Cya-EC is specific to HT22 cells.
In summary, we have characterized an epicatechin derivative that increases GSH synthesis and
protects cells from oxidative stress by virtue of its ability to enhance cystine uptake through
its conversion to cysteine and eventually a mixed disulfide. This allows uptake through a variety
of pathways which are not subject to the same problems and constraints as system xc−. Thus,
this derivative has the potential to enhance GSH synthesis under a wide variety of forms of
toxic stress.
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(A) Dose dependent effect of Cya-EC on the survival of glutamate-treated HT22 cells. Cells
were untreated or treated with increasing concentrations of Cya-EC in the presence of 5 mM
glutamate. 24 hr later cell survival was measured by the MTT assay. The results are the average
± SEM of five independent experiments. (B) Cya-EC protects primary cortical cultures from
oxidative glutamate toxicity. 2 day rat primary cortical cultures were treated with 5 or 10 mM
glutamate alone or in the presence of 25 μM Cya-EC. 24 hr later cell survival was measured
by the MTT assay. The results are the average ± SEM of three independent experiments. (C)
Cya-EC protects HT22 cells from homocysteic acid (HCA) and quisqualate. Cells were treated
with 1 mM HCA or 250 μM quisqualate in the absence or presence of 10 μM Cya-EC. 24 hr
later cell survival was measured by the MTT assay. The results are the average ± SEM of three
independent experiments.
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(A) Dose dependent effect of Cya-EC on the maintenance of GSH levels in glutamate-treated
HT22 cells. Cells were treated with 5 mM glutamate alone or in the presence of increasing
concentrations of Cya-EC. GSH levels were measured after 8 hr and normalized to total protein.
The results are the average ± SEM of three independent experiments. (B) Time dependent
effect of Cya-EC on the maintenance of GSH levels in glutamate-treated HT22 cells. Cells
were treated with 5 mM glutamate alone or in the presence of 10 μM Cya-EC. GSH levels
were measured after 2-8 hr and normalized to total protein. The results are the average ± SEM
of three independent experiments. (C) The glutamate cysteine ligase inhibitor, BSO, blocks
the effects of Cya-EC on the maintenance of GSH levels and cell survival. Cells were treated
with 5 mM glutamate alone, 5 mM glutamate + 10 μM Cya-EC or 5 mM glutamate + 10 μM
Cya-EC in the presence of increasing concentrations of BSO. Cell survival was measured after
24 hr by the MTT assay. GSH levels were measured after 8 hr and normalized to total protein.
The results are the average ± SEM of three independent experiments.
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(A) Time dependent effect of Cya-EC on 35S-cystine uptake in HT22 cells. Cells were treated
with 25 μM 35S-cystine alone or in the presence of 10 μM Cya-EC. After solubilization of the
cells in 0.2 M NaOH, aliquots were taken for scintillation counting and protein determination.
Results are presented as cpm taken up per μg cellular protein. Similar results were obtained in
three independent experiments. (B) Dose dependent effect of Cya-EC on 35S-cystine uptake
in HT22 cells. Cells were treated for 50 min with 25 μM 35S-cystine alone or in the presence
of increasing concentrations of Cya-EC. After solubilization of the cells in 0.2 M NaOH,
aliquots were taken for scintillation counting and protein determination. Results are presented
as cpm taken up per μg cellular protein. Similar results were obtained in three independent
experiments. (C) Correlation between the dose dependent effects of Cya-EC on 35S-cystine
uptake and GSH maintenance. (D) Effect of pretreatment time on the Cya-EC-mediated
increase in 35S-cystine uptake. Cya-EC was added to 35S-cystine immediately before addition
to the cells or incubated with 35S-cystine at 37oC for 10-50 min before addition to the cells for
10 min. After solubilization of the cells in 0.2 M NaOH, aliquots were taken for scintillation
counting and protein determination. Results are the average ± SEM of three independent
experiments. (E) Cya-EC does not protect from cystine deprivation. HT22 cells were treated
with 5 mM glutamate or cystine-free DME alone or in the presence of 10 μM Cya-EC. 24 hr
later cell survival was measured by the MTT assay. The results are the average ± SEM of three
independent experiments.
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RP-HPLC profiles of Cys-EC (A), Cya-EC (B) and the incubation mixture of cystine and Cya-
EC in Hank's balanced solution at 37°C at t = 0 (C) and t = 50 min (D). Column: Kromasil 100
C18 (250 × 4 mm i.d.) 5 μm particle size. Eluents: [A] 0.1% (v/v) aqueous TFA; [B] 0.09%
TFA in water-acetonitrile (1:4). Gradient elution: 8-30% [B] over 30 min, at a flow rate of 1
ml/min. Load: 90 μl. Detection at 214 nm.
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Cysteine but not glutamate or quisqualate inhibit Cya-EC-mediated 35S-cystine uptake. Cells
were treated with 25 μM 35S-cystine alone or in the presence of 10 μM Cya-EC along with
either 5 mM glutamate, 250 μM quisqualate, 5 mM cysteine or 5 mM cystine, added to the
labeling mixture just before addition to the cells for 10 min. After solubilization of the cells in
0.2 M NaOH, aliquots were taken for scintillation counting and protein determination. Results
are presented as the percent of uptake in the absence of glutamate, quisqualate, cysteine or
cystine. Similar results were obtained in three independent experiments. * indicates
significantly different from control.
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Effects of cysteine transporter inhibitors on Cya-EC-mediated increases in 35S-cystine uptake
and the maintenance of GSH levels and cell survival in glutamate-treated HT22 cells. For the
measurement of 35S-cystine uptake, cells were treated with 25 μM 35S-cystine in the presence
of 10 μM Cya-EC alone or along with 5 mM BCH, 5 mM D-serine, 5 mM arginine, 5 mM
serine, 100 μM TBOA or 5 mM MAIBA which were added to the labeling mixture just before
addition to the cells for 10 min. After solubilization of the cells in 0.2 M NaOH, aliquots were
taken for scintillation counting and protein determination. For the measurement of GSH, cells
were treated with 5 mM glutamate alone or in the presence of 10 μM Cya-EC alone or along
with 5 mM BCH, 5 mM D-serine, 5 mM arginine, 5 mM serine, 100 μM TBOA or 5 mM
MAIBA. GSH levels were measured after 8 hr by a chemical assay and normalized to total
protein. For the measurement of cell survival, cells were treated with 5 mM glutamate alone
or in the presence of 10 μM Cya-EC alone or along with 5 mM BCH, 5 mM D-serine, 5 mM
arginine, 5 mM serine, 100 μM TBOA or 5 mM MAIBA. Cell survival was measured after 24
hr by the MTT assay. Results are the average ± SEM of three independent experiments. *
indicates significantly different from Cya-EC alone.
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Effect of cysteamine (Cya) on cell survival (A) and 35S-cystine uptake and cell survival in
glutamate-treated HT22 cells (B). For the measurement of cell survival, cells were treated with
5 mM glutamate alone or in the presence of increasing doses of (A) Cya or (B) 10 μM Cya
alone or along with 5 mM BCH, 5 mM D-serine, 5 mM arginine, 5 mM serine, 100 μM TBOA
or 5 mM MAIBA. Cell survival was measured after 24 hr by the MTT assay. For the
measurement of 35S-cystine uptake, cells were treated with 25 μM 35S-cystine in the presence
of 10 μM Cya alone or along with 5 mM BCH, 5 mM D-serine, 5 mM arginine, 5 mM serine,
100 μM TBOA or 5 mM MAIBA which were added to the labeling mixture just before addition
to the cells for 10 min. After solubilization of the cells in 0.2 M NaOH, aliquots were taken
for scintillation counting and protein determination. Results are the average ± SEM of three
independent experiments. * indicates significantly different from Cya alone.
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Effect of different EC conjugates on 35S-cystine uptake (A) and the maintenance of GSH levels
and cell survival in glutamate-treated HT22 cells (B). For the measurement of 35S-cystine
uptake, cells were treated with 25 μM 35S-cystine in the presence of 10 μM of each of the
conjugates or EC for 10 min following a 50 min pre-incubation at 37°C. After solubilization
of the cells in 0.2 M NaOH, aliquots were taken for scintillation counting and protein
determination. For the measurement of GSH, cells were treated with 5 mM glutamate alone or
in the presence of 10 μM of each of the conjugates. GSH levels were measured after 8 hr by a
chemical assay and normalized to total protein. For the measurement of cell survival, cells
were treated with 5 mM glutamate alone or in the presence of 10 μM of each of the conjugates.
Cell survival was measured after 24 hr by the MTT assay. Results are the average ± SEM of
three independent experiments. * indicates significantly different from glutamate alone.
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Proposed mechanism for the conversion of cystine to cysteine and a mixed disulfide by Cya-
EC.
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